Insignificant disease among men with intermediate-risk prostate cancer

World Journal of Urology

Volumn 32, Issue 6, 2014, Pages 1417-1421

  Hong, Sung Kyu ^a,b   Vertosick, Emily ^a   Sjoberg, Daniel D ^a   Scardino, Peter T ^a,c   Eastham, James A ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Seoul National University Bundang Hospital   (South Korea)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Insignificant; Intermediate risk; Prediction; Prostate; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; BLOOD; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT SELECTION; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84911925287     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1413-3     Document Type: Article

References (19)

1. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS (2012) Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 62:462–468
2. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677
3. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J (2013) Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol 63:101–107
4. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR (2011) Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 29:228–234
5. Van der Kwast TH (2012) The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer. Eur Urol 62:469–471
6. Ahmed HU (2013) Prostate cancer: time for active surveillance of intermediate-risk disease? Nat Rev Urol 10:6–8
7. Mohler J, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National Comprehensive Cancer Network (2013) Prostate cancer, version 1.2014. J Natl Compr Cancer Netw 11:1471–1479
8. Reese AC, Pierorazio PM, Han M, Partin AW (2012) Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80:1075–1079
9. ®). Prostate cancer v4.2013. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
10. Hong SK, Poon BY, Sjoberg DD, Scardino PT, Eastham JA (2014) Prostate size and adverse pathologic features in men undergoing radical prostatectomy. Urology 84:153–157
11. Udo K, Cronin AM, Carlino LJ, Savage CJ, Maschino AC, Al-Ahmadie HA, Gopalan A, Tickoo SK, Scardino PT, Eastham JA, Reuter VE, Fine SW (2013) Prognostic impact of subclassification of radical prostatectomy positive margins by linear extent and Gleason grade. J Urol 189:1302–1307
12. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374
13. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185:121–125
14. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60:291–303
15. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA (2010) The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 58:90–95
16. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH (2007) Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177:107–112
17. Nakanishi H, Wang X, Ochiai A, Trpkov K, Yilmaz A, Donnelly JB, Davis JW, Troncoso P, Babaian RJ (2007) A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 110:2441–2447
18. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC (2014) Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systemic review. Eur Urol 65:1023–1031
19. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C (2013) Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genom 14:690